Clinical Characteristics and Real-World Outcomes of Hypertrophic Cardiomyopathy Patients Undergoing ICD Implantation
International Heart Journal · 2026
DOI: 10.1536/ihj.26-175 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Heart Journal, 2026. Verfasst von Yoshiyasu Aizawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Nippon Medical School Hospital. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Death, Sudden, Cardiac, Defibrillators, Implantable. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Implantable cardioverter-defibrillator (ICD) therapy is essential for preventing sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM). However, real-world data regarding transvenous ICD (TV-ICD) and subcutaneous ICD (S-ICD) systems in patients with HCM remain limited.We retrospectively analyzed 279 patients diagnosed with HCM at Nippon Medical School Hospital between 2003 and 2025. Among them, 75 patients who underwent ICD implantation were included. Baseline characteristics, ICD therapies, and device-related complications were compared between TV-ICD and S-ICD groups.Of the 75 patients, 63 received TV-ICDs and 12 received S-ICDs. Patients in the S-ICD group were younger and taller, with shorter follow-up duration. Established risk factors for sudden cardiac death were generally more frequent in the TV-ICD group, with significant differences in syncope and inducible ventricular fibrillation. During follow-up, there were no significant differences between groups in total ICD therapies, appropriate shocks, inappropriate shocks, or mortality. Anti-tachycardia pacing (ATP) was observed exclusively in the TV-ICD group. Device infections requiring system removal occurred only in the TV-ICD group.In this single-center observational cohort, no statistically significant differences in major clinical outcomes were observed between S-ICD and TV-ICD groups during follow-up. Given its favorable complication profile, S-ICD may represent a feasible alternative in selected younger patients with HCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Nippon Medical School Hospital.
Zitieren
APA
Aizawa, Y., Hayashi, H., Hirayama, H., Okajima, S., Koyama, K., Ito, N., Hachisuka, M., Fujimoto, Y., Tokita, Y., Yodogawa, K., Iwasaki, Y. K., & Asai, K. (2026). Clinical Characteristics and Real-World Outcomes of Hypertrophic Cardiomyopathy Patients Undergoing ICD Implantation. International Heart Journal. https://doi.org/10.1536/ihj.26-175
Vancouver
Aizawa Y, Hayashi H, Hirayama H, Okajima S, Koyama K, Ito N, et al. Clinical Characteristics and Real-World Outcomes of Hypertrophic Cardiomyopathy Patients Undergoing ICD Implantation. International Heart Journal. 2026. doi:10.1536/ihj.26-175
BibTeX
@article{Aizawa2026,
author = {Aizawa, Yoshiyasu and Hayashi, Hiroshi and Hirayama, Hiroaki and Okajima, Shuhei and Koyama, Kentaro and Ito, Nobuaki and Hachisuka, Masato and Fujimoto, Yuhi and Tokita, Yukichi and Yodogawa, Kenji and Iwasaki, Yu-Ki and Asai, Kuniya},
title = {Clinical Characteristics and Real-World Outcomes of Hypertrophic Cardiomyopathy Patients Undergoing ICD Implantation},
journal = {International Heart Journal},
year = {2026},
doi = {10.1536/ihj.26-175}
}
EUVIMED